OrbiMed Leads $30M Round In Innovative Drug Developer Zai Lab

Pan Yue
June 29, 2017 — 12:36 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: biotech China chinese healthcare investment medicine new horizon capital OrbiMed pharmaceutical Private Equity qiming Sequoia Sequoia Capital Sequoia Capital China Shanghai venture capital Zai Lab

Related News:

Saudi Public Investment Fund (PIF) Reveals Plans to Open New Offices in China

December 13, 2023 — 02:00

Saudi Arabia’s FoFs Jada Backs eWTP Arabia Capital’s Second Fund

December 9, 2023 — 02:30

China To Expand Investment Scope for Its National Social Security Fund

December 8, 2023 — 00:03

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

KKR Leads $180 Million Series F Round In Newly-Minted Asian Unicorn Livspace

February 15, 2022 — 03:32

US-Listed Chinese Companies Rush To List In Hong Kong

January 28, 2021 — 07:25

Chinese Investors Jump On The SPAC Bandwagon

January 27, 2021 — 06:02

Franchising and Licensing Asia (FLAsia) 2024